Groundbreaking research revealed that combining immunotherapy with chemotherapy before lung cancer surgery leads to significantly better long-term survival rates. In a clinical trial involving 358 patients with resectable non-small cell lung cancer, the addition of the anti-PD-1 immunotherapy drug nivolumab to standard chemotherapy resulted in remarkable outcomes. Published in the prestigious New England Journal of Medicine in 2022, the initial trial results prompted the Food and Drug Administration to approve this novel immunotherapy/chemotherapy combination as the new standard of care for operable non-small cell lung cancer patients. This innovative approach offers hope and a potential life-saving treatment option for individuals battling this challenging disease. Stay tuned for more updates on the latest advancements in cancer immunotherapy.
Read more about this — here
